Teligent, Inc. (TLGT) は上場企業です ヘルスケア セクターの Drug Manufacturers - Specialty & Generic 業界で事業展開. 本社所在地は Buena, NJ, アメリカ. 現CEOは Timothy Sawyer.
TLGT を有する IPO日 1981-07-30, 142 名の正社員, に上場 NASDAQ Global Select.
Teligent, Inc., formerly Igi Laboratories Inc, is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 35 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2018. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 20 Abbreviated New Drug Application (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2018.
